Cimzia (certolizumab pegol) Letter of Medical Necessity
Cimzia (certolizumab pegol) is uniquely positioned for patients who are pregnant or planning pregnancy due to its minimal placental transfer. Letters of Medical Necessity citing reproductive considerations or specific TNF preference are common avenues for approval.
FDA-Approved Indications
- ● rheumatoid arthritis
- ● psoriatic arthritis
- ● ankylosing spondylitis
- ● non-radiographic axial spondyloarthritis
- ● plaque psoriasis
- ● Crohn's disease
Why Cimzia Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy: methotrexate or other csDMARD trial not documented
- 2. Other TNF inhibitor (Humira, Enbrel, Remicade) preferred
- 3. TB screening not on file
- 4. Pregnancy-specific indication not adequately justified
- 5. Quantity limit exceeded
What to Include in a Cimzia Letter of Medical Necessity
Document the diagnosis with specificity, prior csDMARD or topical/phototherapy failures, TB and hepatitis screening, and clinical rationale for PEGylated TNF inhibition — particularly relevant for women of childbearing potential, lactating patients, or those with prior TNF intolerance where the PEGylated structure may be tolerated.
Key clinical evidence to cite:
- ✓ RAPID 1 & 2 trials (RA)
- ✓ RAPID-PsA, RAPID-axSpA, CIMPASI 1 & 2 trials
- ✓ CRIB and CRADLE studies — minimal placental transfer in pregnancy and lactation
Relevant guidelines:
- 📖 ACR 2021 RA Guidelines
- 📖 AAD-NPF 2019 Psoriasis Guidelines
- 📖 ACR/SAA/SPARTAN 2019 axSpA Guidelines
Cimzia Prior Authorization Criteria
Standard criteria across major US payers for Cimzia. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy: methotrexate or other csDMARD trial not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Cimzia
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Cimzia Prior Authorization FAQ
Why was my Cimzia prior authorization denied?
The most common denial reasons for Cimzia are: Step therapy: methotrexate or other csDMARD trial not documented; Other TNF inhibitor (Humira, Enbrel, Remicade) preferred; TB screening not on file; Pregnancy-specific indication not adequately justified; Quantity limit exceeded.
What should a Cimzia Letter of Medical Necessity include?
Document the diagnosis with specificity, prior csDMARD or topical/phototherapy failures, TB and hepatitis screening, and clinical rationale for PEGylated TNF inhibition — particularly relevant for women of childbearing potential, lactating patients, or those with prior TNF intolerance where the PEGylated structure may be tolerated.
Which payers cover Cimzia?
Cimzia is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Humana, though formulary tier and prior authorization criteria vary.